UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 105

Sortiert nach

Tamoxifen and pregnancy: an absolute contraindication?

Breast cancer research and treatment, 2019-05, Vol.175 (1), p.17-25

2019

Volltextzugriff (PDF)

Strategies to target drugs to gliomas and CNS metastases of solid tumors

Journal of Neurology, 2016-03, Vol.263 (3), p.428-440

2016

Volltextzugriff (PDF)

The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy

European journal of nuclear medicine and molecular imaging, 2024-02, Vol.51 (3), p.820-827

2024

Volltextzugriff (PDF)

Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique

Intensive care medicine, 2013-05, Vol.39 (5), p.977-978

2013

Volltextzugriff (PDF)

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer

Investigational new drugs, 2015-12, Vol.33 (6), p.1197-1205

2015

Volltextzugriff (PDF)

Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients

Cancer chemotherapy and pharmacology, 2023-06, Vol.91 (6), p.447-456

2023

Volltextzugriff (PDF)

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine

Cancer chemotherapy and pharmacology, 2012, Vol.69 (1), p.25-33

2012

Volltextzugriff (PDF)

Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction

Cancer chemotherapy and pharmacology, 2014, Vol.73 (1), p.113-124

2014

Volltextzugriff (PDF)

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature

Cancer chemotherapy and pharmacology, 2022-07, Vol.90 (1), p.97-104

2022

Volltextzugriff (PDF)

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy

Cancer chemotherapy and pharmacology, 2015-04, Vol.75 (4), p.763-772

2015

Volltextzugriff (PDF)

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome

Breast cancer research and treatment, 2017-02, Vol.161 (3), p.567-574

2017

Volltextzugriff (PDF)

Pharmacokinetics and Clinical Efficacy of Phenobarbital in Asphyxiated Newborns Treated with Hypothermia: A Thermopharmacological Approach

Clinical pharmacokinetics, 2012-10, Vol.51 (10), p.671-679

2012

Volltextzugriff (PDF)

A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors

EJNMMI research, 2021-08, Vol.11 (1), p.73-73, Article 73

2021

Volltextzugriff (PDF)

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

Cancer chemotherapy and pharmacology, 2017-12, Vol.80 (6), p.1171-1178

2017

Volltextzugriff (PDF)

Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs

Clinical pharmacokinetics, 2023-08, Vol.62 (8), p.1157-1167

2023

Volltextzugriff (PDF)

Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors

Cancer chemotherapy and pharmacology, 2021-02, Vol.87 (2), p.269-276

2021

Volltextzugriff (PDF)

Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

Cancer chemotherapy and pharmacology, 2020-07, Vol.86 (1), p.163-163

2020

Volltextzugriff (PDF)

A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Clinical pharmacokinetics, 2020-02, Vol.59 (2), p.207-216

2020

Volltextzugriff (PDF)

Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II

Investigational new drugs, 2017-08, Vol.35 (4), p.478-490

2017

Volltextzugriff (PDF)

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Clinical pharmacokinetics, 2010-08, Vol.49 (8), p.493-507

2010

Volltextzugriff (PDF)

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

Clinical pharmacokinetics, 2014-04, Vol.53 (4), p.305-325

2014

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing

Clinical pharmacokinetics, 2017-09, Vol.56 (9), p.987-997

2017

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology

Clinical pharmacokinetics, 2022-12, Vol.61 (12), p.1649-1675

2022

Volltextzugriff (PDF)

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation

Clinical pharmacokinetics, 2019-05, Vol.58 (5), p.627-637

2019

Volltextzugriff (PDF)

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes

Cancer chemotherapy and pharmacology, 2019-09, Vol.84 (3), p.487-499

2019

Volltextzugriff (PDF)

1 – 25 von 105

Suche als RSS-Feed

Aktive Filter

ThemaMedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(105)

Sprache

Englisch
(105)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Tamoxifen and pregnancy: an absolute contraindication?

Strategies to target drugs to gliomas and CNS metastases of solid tumors

The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy

Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer

Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine

Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome

Pharmacokinetics and Clinical Efficacy of Phenobarbital in Asphyxiated Newborns Treated with Hypothermia: A Thermopharmacological Approach

A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs

Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors

Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes

Aktive Filter

Suchergebnisse filtern